Balyasny Asset Management L.P. Buys Shares of 44,315 Nuvalent, Inc. (NASDAQ:NUVL)

Balyasny Asset Management L.P. bought a new stake in Nuvalent, Inc. (NASDAQ:NUVL - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 44,315 shares of the company's stock, valued at approximately $3,469,000. Balyasny Asset Management L.P. owned about 0.06% of Nuvalent as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in NUVL. Crowley Wealth Management Inc. bought a new stake in Nuvalent in the fourth quarter valued at $27,000. Quarry LP bought a new stake in Nuvalent in the fourth quarter valued at $39,000. US Bancorp DE bought a new stake in Nuvalent in the fourth quarter valued at $90,000. KBC Group NV lifted its stake in Nuvalent by 61.1% in the fourth quarter. KBC Group NV now owns 1,587 shares of the company's stock valued at $124,000 after buying an additional 602 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in Nuvalent by 13.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 2,618 shares of the company's stock valued at $205,000 after buying an additional 309 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NUVL has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $110.00 target price on shares of Nuvalent in a research note on Monday, March 3rd. Wedbush restated an "outperform" rating and set a $115.00 price objective on shares of Nuvalent in a research note on Monday, January 13th. Finally, UBS Group upgraded shares of Nuvalent from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $115.50.

Insider Buying and Selling

In related news, Director Matthew Shair sold 2,000 shares of Nuvalent stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $78.43, for a total value of $156,860.00. Following the transaction, the director now owns 216,522 shares of the company's stock, valued at approximately $16,981,820.46. This trade represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $78.46, for a total value of $2,118,420.00. Following the completion of the transaction, the chief executive officer now directly owns 249,062 shares in the company, valued at $19,541,404.52. This represents a 9.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 83,000 shares of company stock valued at $6,185,150 over the last three months. Company insiders own 12.52% of the company's stock.

Nuvalent Stock Down 2.4%

NASDAQ:NUVL opened at $69.85 on Monday. The business's 50-day moving average price is $71.41 and its 200 day moving average price is $80.31. The firm has a market cap of $5.00 billion, a P/E ratio of -20.13 and a beta of 1.42. Nuvalent, Inc. has a 52-week low of $55.54 and a 52-week high of $113.51.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.14) by ($0.04). During the same period in the previous year, the business earned ($0.69) earnings per share. Sell-side analysts expect that Nuvalent, Inc. will post -3.86 EPS for the current year.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.